×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LLY – eli lilly and company (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LLY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/17
08:00 am
lly
Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.
Low
Report
Eli Lilly and Company (LLY) was downgraded by HSBC Holdings plc from "hold" to "reduce". They now have a $850.00 price target on the stock.
3/17
04:31 am
lly
Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]
Low
Report
Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day [Fortune]
3/16
05:21 pm
lly
Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]
Low
Report
Wall Street Firms Turn Bullish on Eli Lilly and Company (LLY) Buoyed by GLP-1 Medication Expansion Plans [Yahoo! Finance]
3/16
12:29 pm
lly
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]
Low
Report
Is There Too Much Bullishness Priced Into Eli Lilly's Stock Price? [Yahoo! Finance]
3/16
12:29 pm
lly
Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]
Low
Report
Eli Lilly Pediatric EBGLYSS Data Strengthens Broader Immunology Growth Story [Yahoo! Finance]
3/16
08:12 am
lly
LYB names David Dennison as head of investor relations; Dave Kinney to retire [Yahoo! Finance]
Low
Report
LYB names David Dennison as head of investor relations; Dave Kinney to retire [Yahoo! Finance]
3/16
08:07 am
lly
Structure's obesity pill shows up to 16.3% weight loss in study [BNN Bloomberg (Canada)]
Low
Report
Structure's obesity pill shows up to 16.3% weight loss in study [BNN Bloomberg (Canada)]
3/16
06:59 am
lly
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis [Yahoo! Finance]
Low
Report
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/6
04:36 pm
lly
Form PRE 14A ELI LILLY & Co For: Mar 06
Low
Report
Form PRE 14A ELI LILLY & Co For: Mar 06
2/19
04:19 pm
lly
Form 4 ELI LILLY & Co For: Feb 19 Filed by: Dozier Eric
Low
Report
Form 4 ELI LILLY & Co For: Feb 19 Filed by: Dozier Eric
2/18
04:27 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Sulzberger Gabrielle
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Sulzberger Gabrielle
2/18
04:26 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: LUCIANO JUAN R
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: LUCIANO JUAN R
2/18
04:25 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Fyrwald J Erik
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Fyrwald J Erik
2/18
04:24 pm
lly
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Alvarez Ralph
Low
Report
Form 4 ELI LILLY & Co For: Feb 17 Filed by: Alvarez Ralph
2/18
04:23 pm
lly
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Zakrowski Donald A
Low
Report
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Zakrowski Donald A
2/18
04:22 pm
lly
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Montarce Lucas
Low
Report
Form 4 ELI LILLY & Co For: Feb 16 Filed by: Montarce Lucas
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/12
Eli Lilly, AbCellera Biologics to co-develop coronavirus therapies [Reuters]
14.2%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
3/2 U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis 5.8%
4/13 Despite Qualms, Arthritis Drug to Be Tested in Coronavirus Study [The New York Times] 4.6%
4/2 Eli Lilly And Co (NYSE: LLY) had its price target lowered by analysts at Morgan Stanley from $150.00 to $148.00. They now have an "overweight" rating on the stock. 4.2%
3/23 FDA enacts abbreviated approval pathway for insulin biosimilars [Seeking Alpha] 3.2%
4/16 Lower-priced versions of Humalog® Mix75/25™ KwikPen® and Humalog® Junior KwikPen® now available 3.2%
10/28 Insider Buying: The Eli Lilly and Company (NYSE:LLY) Chairman Just Bought US$500k Worth Of Shares [Yahoo! Finance News] 2.7%
2/4 Form 4 ELI LILLY & Co For: Feb 01 Filed by: Zulueta Alfonso G 2.7%
12/18 Lilly Announces the Launch of TRIUMPH, the First, Long-Term, Real-World Evidence Study of Emgality® (galcanezumab-gnlm) 2.7%
3/23 Lilly Provides Update on Clinical Trial Activities During COVID-19 Pandemic 2.6%
TOP News Decliners
3/11
Eli Lilly to Participate in Program to Make Insulin Cheaper for Seniors [The Motley Fool]
-10.0%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
3/18 Hap Sneddon's Top Picks: March 18, 2020 [Business News Network (BNN) Energy & Resources (Canada)] -7.6%
3/20 Form DEFA14A ELI LILLY & Co -5.8%
7/11 New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache -5.3%
6/9 Lilly's ultra rapid lispro provided similar A1C reductions compared to Humalog® (insulin lispro), with superior post-meal blood glucose reductions -4.0%
8/14 Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health -4.0%
4/28 Form 8-K ELI LILLY & Co For: Apr 24 -3.5%
2/27 Local Organization NOVA ScriptsCentral Benefits BIG with Eli Lilly release of Bulk Donation Insulin Pens -3.4%
2/21 Trulicity® (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease -3.4%
8/5 Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments -3.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: